Fig. 3: In-depth analysis of B cells and plasma cells from patients given LD IL-2 treatment.
From: Low-dose IL-2 enhances the generation of IL-10-producing immunoregulatory B cells
a Diagrammatic schema summarising the three treatment groups of the trial. Patients received either saline, or 1.5 × 106 IU, or 2.5 × 106 IU IL-2. b Proportion of IL-10-positive B cells in patients prior to and following the administration saline (left) or 1.5 × 106 IU IL-2 (right). n = 4 and 6 analysed by flow cytometry of untreated and treated groups respectively. p-values generated using a paired two-tailed parametric t-test. *p < 0.05. c Representative flow cytometry plot of IL-10 expressing B cells pre- and post-LD IL-2. d Uniform manifold approximation and projection of four clusters of all B and plasma cells from all samples analysed by scRNAseq: Naïve, non-switched memory and switched memory B cells and plasma cells (left). Dot plot of enriched identifying genes of each cluster (right). e Proportion of each cell type before treatment and following saline or LD IL-2 treatment. LD IL-2 treatment groups combined. p-values generated using an unpaired two-tailed parametric t-test. **p < 0.01 (f) Dotplot showing Breg gene set enrichment (gene signatures from recently published meta-analysis of all human Breg RNAseq studies). The intensity of gene signature expression is indicated by the colour of the dot and proportion of cells expressing this signature is indicated by size of the dot. Source data are provided as a Source Data file.
